Smoking Cessation
Introduction to Bupropion Treatment
- The National Comprehensive Cancer Network recommends starting bupropion 1-2 weeks before the planned quit date, with a dosing regimen of 150 mg orally once daily for the first 3 days, followed by 150 mg orally twice daily (300 mg total daily dose) for 7-12 weeks, with possible extension up to 6 months to 1 year for continued cessation support 1
- Bupropion SR, marketed as Zyban, is the specific formulation used for smoking cessation, as recommended by guidelines from societies such as the American College of Chest Physicians 2
Contraindications and Precautions
- Bupropion is contraindicated in patients with seizure disorders or risk factors for seizures, patients taking MAO inhibitors, patients taking tamoxifen, closed-angle glaucoma, and brain metastases due to seizure risk 1
- Bupropion SR is also contraindicated in patients with a history of eating disorders, as stated by the National Comprehensive Cancer Network 1 and the American College of Chest Physicians 2
Adverse Effects and Monitoring
- Common side effects of bupropion include insomnia, dry mouth, headache, and nausea, while serious but rare side effects include seizures, hypersensitivity reactions, and neuropsychiatric symptoms, such as depression, hostility, and suicidal behavior, according to the American Psychiatric Association 2, the National Comprehensive Cancer Network 1, and 3
- The National Comprehensive Cancer Network notes that bupropion may cause neuropsychiatric symptoms (depression, hostility, suicidal behavior), and patients should be monitored for development or worsening of these issues, particularly in those with a psychiatric history 1
Special Considerations
- Bupropion works by reducing nicotine withdrawal symptoms, modulating dopamine and norepinephrine reuptake, and managing cravings during quit attempts, with its efficacy in smoking cessation appearing independent of its antidepressant effects, according to the American Heart Association 2 and the Mayo Clinic Proceedings 4
- Evidence on effectiveness is limited to medium to heavy smokers (15+ cigarettes per day) receiving behavioral support, as noted by the American College of Chest Physicians 2
- Combining bupropion with nicotine replacement therapy (NRT) may enhance efficacy for some patients who have difficulty quitting with monotherapy, as noted by the Mayo Clinic Proceedings 4
- Bupropion may help reduce weight gain associated with smoking cessation, and combining bupropion with nicotine replacement therapy or behavioral support may enhance efficacy, as supported by multiple guidelines 1, 5, 2, 3
- For patients with moderate to severe hepatic or renal impairment, a dose reduction should be considered, and limited evidence exists for use in light smokers or those with a history of depression, as noted by the American College of Chest Physicians 2 and 3
- Monitoring for neuropsychiatric symptoms is recommended, particularly in patients with a history of psychiatric disorders, and dose adjustments may be necessary for patients with moderate to severe hepatic or renal impairment, as recommended by the National Comprehensive Cancer Network 1 and 3